Home/Pipeline/Asthma Trial

Asthma Trial

Asthma

Phase 3Completed/HighlightedN/A

Key Facts

Indication

Asthma

Phase

Phase 3

Status

Completed/Highlighted

Company

Science 37

About Science 37

Science 37's mission is to make clinical research accessible to anyone, anywhere, anytime by pioneering a decentralized clinical trial (DCT) model. Its key achievement is establishing a unique, FDA-inspected Direct-to-Patient Site, which has successfully supported over 185 trials and consistently ranks as a top-enrolling site. The company's strategy leverages its proprietary technology platform and a nationwide network of research-grade nurses to orchestrate hybrid and fully decentralized trials, offering sponsors a proven path to faster, more diverse patient recruitment and retention.

View full company profile

Therapeutic Areas

Cardiovascular CNS Dermatology Endocrinology Gastroenterology Hematology Immunology Infectious Disease Men’s Health Musculoskeletal Oncology Ophthalmology Respiratory Urology Women’s Health Pediatrics

Other Asthma Drugs

Drug	Company	Phase	Status
Asthma Candidate	Teva	Phase 3	Active
Chitinase Inhibitor	Lead Discovery Siena	Discovery	Active
RIG-101	RIGImmune	Pre-clinical	Active
SKB378	Klus Pharma	Phase 1	Active
Asthma Clinical Trials	American Health Research	Not Disclosed	Active
Advanced Asthma Products	Polpharma	Not Disclosed	Active
Solrikitug	Uniquity Bio	Phase 2	Active
CAL-4	Calyxha Biotechnologies	Preclinical	Active
Flutiform	KYORIN Pharmaceutical	Marketed	Active
Novel Immunology Candidate	Teva Pharmaceutical Industries	Phase 3	Active
Zumilokibart (APG777)	Apogee Therapeutics	Phase 1	Completed (Phase 1b)
APG808	Apogee Therapeutics	Phase 1b	Interim results reported